Novavax (XSWX:NVAX) Institutional Ownership: 35.84% (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NVAX Novavax Inc XSWX:NVAX
46 GF Score
Price CHF7.24
GF Value CHF2.58
! 6 Warning Signs
View Full Analysis

What is Novavax Institutional Ownership?

Novavax XSWX:NVAX +9.21% 46 Institutional Ownership is 35.84% as of Aug. 22, 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 46/100 and a GF Value™ of CHF2.58. The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Novavax's institutional ownership is 35.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Novavax's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Novavax's Float Percentage Of Total Shares Outstanding is 99.36%.

Novavax Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Novavax's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Institutional Ownership Chart

Novavax Historical Data

The historical data trend for Novavax can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 30.26 31.02 31.54 31.53 31.70 31.85 31.98 32.31 35.06 35.84
XSWX:NVAX
46GF Score
Novavax Inc XSWX:NVAX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 35.84% mean?
Novavax (XSWX:NVAX) has a Institutional Ownership of 35.84% as of Aug. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Novavax and its competitors.
Is Novavax's Institutional Ownership too high?
Novavax's current Institutional Ownership is 35.84%. Overall, Novavax has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Institutional Ownership compare to JBIO and AVLN?
Novavax's Institutional Ownership of 35.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Novavax and its competitors. Novavax's current Institutional Ownership is 35.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Institutional Ownership of 35.84%. The stock's GF Value™ is CHF2.58, compared to a current price of CHF7.24 — trading 180.7% above its estimated fair value. The current Institutional Ownership is 35.84%. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Institutional Ownership is 35.84% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.

Key valuation signals for XSWX:NVAX:

  • Institutional Ownership: 35.84%
  • GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for XSWX:NVAX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.24
Price
CHF2.58
GF Value